Wire · operational-macro
Is FDA Valve Repair Approval Altering The Investment Case For Edwards Lifesciences (EW)?
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 November 2026 · Fusion42 review
Edwards Lifesciences received FDA approval for its PASCAL Precision system for tricuspid valve repair and PASCAL Ace with Capture Clarity system for mitral TEER, expanding its transcatheter valve repair portfolio in the U.S. This approval supports forecasts for higher earnings and revenue driven by increased adoption of complex mitral and tricuspid therapies.
This Wire brief sits within Fusion42's coverage of Medtech, and 6 sources have reported it between 21 Oct 2026 and 3 Nov 2026.
◆ ◆ The Wire takeaway
Valve repair approvals in the U.S. widen Edwards Lifesciences' toolkit and boost your opportunity in structural heart interventions. You need to focus on building ties with heart teams adopting these new procedures to capture the growing case volume early.
◆ Coverage
6 sources · first reported 21 Oct 2026 · latest 3 Nov 2026
◆ Related on Wire
◆ Topics